编号：2015-001 证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |-------------------|-----------------------------------------------------------------------------------------------| | | | | 投资者关系活 | 特定对象调研 □分析师会议 | | 动类别 | 媒体采访 √业绩说明会 | | | 新闻发布会 □路演活动 | | | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位名称 | 中国人寿、上海宏铭投资、东方证券、万家基金、上 海证券、中航证券、浙江农资集团、中昂国际投资、 | | | 上海大智慧通讯社等 | | 时间 | 4 月 17 日星期五 | | 地点 | 公司会议室 | | 上市公司接待 人员 | 副董事长、董事会秘书及证券事务代表 | | 投资者关系活 | 1、公司 2014 年度生产经营及 2015 年度工 | | 动主要内容介 | 作重点的介绍。 | | 绍 | 2014 年，宏观经 ...

Group 1: Company Overview and Market Conditions - In 2015, the pharmaceutical industry faced severe challenges, which were anticipated at the beginning of the year. The actual performance aligned closely with these expectations [2] - The year was marked by national drug bidding, with Shaoxing City being a pilot for centralized procurement and pricing mechanisms, intensifying the competitive landscape [2] - Despite efforts to strengthen communication with upstream clients and downstream medical institutions, sales experienced a decline [3] Group 2: Retail Chain Development - The company currently operates over 70 retail chain stores, focusing on enhancing quality rather than merely increasing quantity [3] - Rising personnel costs and store rents, along with new healthcare reforms, have prompted stores to improve their scale and service quality [3] - Four of the company's stores ranked among the top 100 in the recently published list of Chinese pharmacies, with aspirations for more stores to join this ranking in the future [3] Group 3: Stock Market Response and Management Actions - In response to the significant stock market decline in July, regulatory bodies encouraged company executives to buy back shares to stabilize stock prices [4] - The company participated in a joint statement initiated by the Zhejiang Listed Companies Association to maintain market stability and investor confidence [4] Group 4: Production Capacity and Operations - The injection workshop of Zhenyuan Pharmaceutical was certified by the new GMP in September 2014, leading to significant capacity growth [4] - Post-production, there is a necessary adjustment period for personnel and equipment to reach optimal operational levels [4]

Group 1: Policy Impact - The implementation of the "Two Invoice System" is seen as both a crisis and an opportunity for pharmaceutical companies, with the potential for growth if customer needs are accurately identified and service is improved [2][3] - The company is closely monitoring the situation and has successfully adapted to policy changes such as zero markup and secondary pricing negotiations, maintaining sales growth [2] Group 2: Retail Chain Performance - In 2015, the retail chain achieved sales of 440 million RMB, ranking 41st in the national retail enterprise sales list, showing an upward trend despite an overall pessimistic industry outlook [3] - The retail chain employs a "famous store, famous doctor, famous medicine" business model, leveraging the brand recognition of "Zhenyuan Hall" and a rich resource of renowned traditional Chinese medicine practitioners [3] Group 3: DTC Pharmacy Development - The company is exploring the DTC (Direct-to-Consumer) pharmacy model, expanding distribution varieties and retail clinical products, and has opened its first high-end DTC pharmacy next to Shaoxing People's Hospital [4] - Future plans include opening additional DTC pharmacies in large drugstores and hospital-adjacent locations [4] Group 4: Pharmaceutical Sales and Production - In 2015, the sales of Zhenyuan Pharmaceutical's formulations reached nearly 200 million RMB, with a year-on-year growth of 12.55% [4] - The company has made significant improvements in the production process of adenosine and is preparing for large-scale production in 2016, which is expected to positively impact future sales [4][5]

Group 1: Company Performance - In Q1 2016, the company reported a revenue increase of 11.59% year-on-year and a net profit increase of 21.57% attributable to the parent company [2] - The pharmaceutical wholesale sector continued to grow, with retail chains expanding their clinical retail scale [3] - The company achieved sales of 440 million CNY in 2015 for its retail chain, ranking 41st among national retail enterprises [3] Group 2: Retail Chain Development - The retail chain has over 70 stores, with a focus on expanding store numbers and optimizing sales performance [3] - The company has implemented a differentiated competition strategy, promoting the "famous store, famous doctor, famous medicine" model [4] - The retail chain's sales and profit have increased over tenfold since its establishment, consistently ranking among the top national retail pharmacy enterprises since 2006 [4] Group 3: Challenges and Adaptations - The pharmaceutical retail chain faces challenges due to rising labor costs, increased rent in mature locations, and changes in healthcare policies [4] - The company is adjusting its store structure and product mix to enhance traditional Chinese medicine services and expand health service projects [4] - The company has opened a high-end DTC pharmacy next to Shaoxing People's Hospital, with plans for further expansions [4] Group 4: Traditional Chinese Medicine (TCM) Development - The company’s TCM segment has been a focus, with its TCM factory being one of the first in Zhejiang to receive GMP certification [5] - Significant investments have been made to enhance quality control and expand production capacity for TCM products [5] - The company has established multiple medicinal herb planting bases and plans to continue expanding these initiatives [6]

证券代码：000705 证券简称：浙江震元 编号：2016-007 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------|-------------------------|--------------------------------------------------| | | | | | 投资者关系 | √ | 特定对象调研 □分析师会议 | | 活动类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位 | 西南证券 | | | 名称 | | | | 时间 | 2016 年 5 月 20 | 日星期五 | | 地点 上市公司 | 公司会议室 | | | 接待人员 | 董事会秘书 | | | 投资者关系 | 1、请介绍下公司 | 2015 年度、 2016 年一季度经营情 | | 活动主要内 | 况。 | | | 容介绍 | 公司 2015 | 年报、 2016 年一季报已公布。 2015 | | | 年，公司实现营业收入 | ...

证券代码：000705 证券简称：浙江震元 编号：2016-002 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |---------------|------------------------------------------------------| | | | | 投资者关系 | 特定对象调研 □分析师会议 | | 活动类别 | 媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位 名称 | 长盛基金、银河基金、方正证券、前海开源基金 | | 时间 | 2 月 22 日星期一 | | 地点 | 公司会议室 | | 上市公司 | | | 接待人员 | 董事会秘书及证券事务代表 | | 投资者关系 | 1、请介绍下公司 2015 年的整体经营情况？ | | 活动主要内 | 年，药品招投标、二次议价、环保等对公司生产 | | 容介绍 | 经营产生较大影响，公司 2015 年半年报中已有体现。 | | | 三季度公司对医药商业的组织架构、产品结构和人员配 | | | 置等进行调整，加强了医院终端、厂家等客 ...

证券代码：000705 证券简称：浙江震元 编号：2016-004 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |---------------|------------------------------------------------------| | | | | 投资者关系 | 特定对象调研 □分析师会议 | | 活动类别 | 媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位 名称 | 广发证券、毅木资产、吉渊投资、聚泓投资 | | 时间 | 月 24 日星期三 | | 地点 | | | 上市公司 | | | 接待人员 | 董事会秘书及证券事务代表 | | 投资者关系 | 、请介绍下公司 2015 年的整体经营情况？ | | 活动主要内 | 年，药品招投标、二次议价、环保等对公司生产 | | 容介绍 | 经营产生较大影响，公司 2015 年半年报中已有体现。 | | | 三季度公司对医药商业的组织架构、产品结构和人员配 | | | 置等进行调整，加强了医院终端、厂家等客户的沟通、 | | | ...

证券代码：000705 证券简称：浙江震元 编号：2016-003 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |-------------------|-------------------------------------------------------------------------| | | | | 投资者关系 | 特定对象调研 □分析师会议 | | 活动类别 | 媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位 | 平安证券、银华基金、朱雀投资、华宝兴业基金、国联证 | | 名称 | 券、浦银安盛基金、兴证证券、信诚基金、天弘基金、建 信基金、申万菱信基金 | | | | | 时间 | 年 2 月 24 日星期三 | | 地点 | 公司会议室 | | 上市公司 接待人员 | 董事会秘书及证券事务代表 | | 投资者关系 | 、请介绍下公司 2015 年的整体经营情况？ | | 活动主要内 | 年，药品招投标、二次议价、环保等对公司生产 | | 容介绍 | 经营产生较大影响，公司 2 ...

Financial Performance - In 2015, the company achieved an operating income of 2.164 billion yuan and a net profit attributable to shareholders of 36.2256 million yuan [2] - In Q1 2016, the company reported an operating income of 602 million yuan, with a net profit of 8.2783 million yuan, representing a year-on-year growth of 21.57% [3] - For 2015, the sales of the company's formulation products reached 191 million yuan, marking a year-on-year increase of 12.55% [4] Market and Regulatory Environment - The company is closely monitoring the implementation of the "Two Invoice System" as part of the healthcare reform, which has sparked widespread discussion in the market [3] - The company has established a logistics subsidiary to enhance its third-party logistics capabilities, which is crucial given the regulatory environment surrounding pharmaceutical distribution [3][4] Strategic Initiatives - The company has formed a bidding coordination committee to adapt to changes in bidding policies, resulting in satisfactory bidding outcomes [4] - The company aims to leverage its strengths in traditional Chinese medicine and its good relationships with hospitals to build a comprehensive health platform, positioning itself as a key player in the health industry [4][5] Future Outlook - The company plans to continuously improve its logistics capabilities and service quality to attract third-party pharmaceutical enterprises [4] - The "13th Five-Year Plan" emphasizes "Healthy China" as a national strategy, which aligns with the company's future direction in health services [4][5]

证券代码：000705 证券简称：浙江震元 编号：2016-005 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |---------------|--------------------------------------------------------------| | | | | 投资者关系 | 特定对象调研 □分析师会议 | | 活动类别 | 媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位 名称 | | | | | | 时间 地点 | 4 月 28 日星期四 公司会议室 | | 上市公司 | | | 接待人员 | 董事会秘书及证券事务代表 | | 投资者关系 | 、请介绍下公司 2015 年年报及 2016 年一季报情 | | 活动主要内 | | | 容介绍 | 2015 年报、 2016 年一季报已于 2016 年 4 月 | | | 日发布。 2015 年，公司实现营业收入 21.64 亿 | | | 元 ， 归 属 于 上 市 公 司 股 东 的 净 利 润 3,622.56 万 | ...